Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Epidermal Growth Factor Receptor Mutations”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT04391283
What this trial is testing

First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting

Who this might be right for
Carcinoma, Non-Small-Cell Lung
First Affiliated Hospital of Zhejiang University 500
Testing effectiveness (Phase 2)UnknownNCT01714908
What this trial is testing

Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21

Who this might be right for
Non-small Cell Lung Cancer
Jinming Yu 100
Large-scale testing (Phase 3)Looking for participantsNCT06982521
What this trial is testing

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Who this might be right for
PIK3CA MutationHER2- Negative Breast CancerHormone Receptor Positive Tumor+3 more
Relay Therapeutics, Inc. 540
Not applicableStudy completedNCT01081496
What this trial is testing

Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 1,000
Not applicableUnknownNCT04304638
What this trial is testing

Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

Who this might be right for
Non Small Cell Lung CancerStage III Non-small-cell Lung CancerEGFR Mutation-Related Tumors
Chinese Academy of Medical Sciences 450
Testing effectiveness (Phase 2)UnknownNCT04882345
What this trial is testing

Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment

Who this might be right for
Lung CancerEGFR Gene Mutation
Shanghai Chest Hospital 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT04027647
What this trial is testing

Phase 2 Study of Dacomitinib in NSCLC

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IIICNSCLC Stage IV+2 more
National Cancer Centre, Singapore 118
Early research (Phase 1)Study completedNCT02947386
What this trial is testing

Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer

Who this might be right for
EGFR Gene MutationRecurrent Non-Small Cell Lung CarcinomaStage IIIA Non-Small Cell Lung Cancer+2 more
Roswell Park Cancer Institute 7
Not applicableStudy completedNCT02131259
What this trial is testing

Long-term Observation PMS for Afatinib

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 1,605
Not applicableStudy completedNCT00883480
What this trial is testing

Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma

Who this might be right for
Non-small Cell Lung Cancer
Spanish Lung Cancer Group 153
Large-scale testing (Phase 3)Looking for participantsNCT06735391
What this trial is testing

A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

Who this might be right for
Locally Advanced or Metastatic Non-squamous NSCLCHarboring EGFR Sensitive Mutations NSCLCPreviously Untreated Systematically NSCLC
Shanghai JMT-Bio Inc. 516
Not applicableStudy completedNCT04552613
What this trial is testing

Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients

Who this might be right for
Non-small-lung-cell CancerNSCLCEGFR Gene Mutation
The Fourth Affiliated Hospital of Zhejiang University School of Medicine 114
Testing effectiveness (Phase 2)UnknownNCT02036359
What this trial is testing

Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca

Who this might be right for
Non-small Cell Lung Cancer(NSCLC)
National Taiwan University Hospital 76
Testing effectiveness (Phase 2)Looking for participantsNCT05104788
What this trial is testing

Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Peking University Cancer Hospital & Institute 27
Testing effectiveness (Phase 2)Active Not RecruitingNCT06940401
What this trial is testing

JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations

Who this might be right for
NSCLC
Suzhou Junjing BioSciences Co., Ltd. 44
Early research (Phase 1)Study completedNCT03446417
What this trial is testing

ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Zeno Pharmaceuticals, Inc. 34
Not applicableStudy completedNCT02991274
What this trial is testing

ARTEMIS DIANE T790M (An Amino Acid Substitution at Position 790 in EGFR, From a Threonine (T) to a Methionine (M)) Mutation at Hospital Laboratories in Comparison With Central Laboratory

Who this might be right for
Locally Advanced or Metastatic EGFR(+) NSCLC Patients
AstraZeneca 897
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06319950
What this trial is testing

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

Who this might be right for
Lung Cancer, Nonsmall Cell
Taizhou Hospital 255
Post-approval studies (Phase 4)Study completedNCT04511533
What this trial is testing

Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations

Who this might be right for
Metastatic Non Small Cell Lung Cancer
Pfizer 101
Testing effectiveness (Phase 2)Study completedNCT02442349
What this trial is testing

Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 171
Next Page